A Phase 1/2 interventional study of SENS-601 administration in GJB2 Gene Mutation, DFNB1A and Congenital Deafness, sponsored by Sensorion. Recruiting at 1 site in France. Open to participants aged 6 Months to 6 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sensorion · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Deafness with a site in France — 12 open to participants now, 13 under way, none of them phase 3. Deafness · France.
Among the 42 studies in Deafness with a site in France, this one is the 20th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 1/2, reaches primary completion later than 12 of the 12 other live ones, and was the 42nd registered.
160 studies on the registry are indexed under Deafness; 46 are open to participants now.
Browse Deafness studies →12 of the 42 studies in Deafness with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 32 mo–48 mo
University Hospital, Lille · Sites in France
Ages 50+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 1 days–2 yrs
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 11 mo–21 mo
University Hospital, Toulouse · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 29 Deafness studies recruiting now, 11 (38%) set no upper age limit and 9 (31%) stop at 75 or younger; 18 take children under 18; 5 take healthy volunteers.
This study: 6 Months to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 18 is below the median of 43 across 106 interventional studies indexed under Deafness.
Median enrollment 55 across the 24 interventional studies, 72 across the 18 observational. Of the 23 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 42 have an industry lead sponsor. The 10 most frequent:
Sensorion is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Sensorion has 3 studies filed under Deafness — fewer than ten, so there is no comparison to draw.
5 of the studies in Deafness with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06499584CHU de ReimsStudy of the Fine Structure and Temporal Envelope of the Human Cochlea in Response to Human Vocalizations | 2026-12 |
| NCT05325450University Hospital, ToulouseOptimization of Hearing Performance in the Subject Implanted | 2027-01-18 |
| NCT04495660University Hospital, ToulouseRestauration of the Auditory and Cognitive Functions in Cochlear Implanted Deaf Children in fNIRS | 2027-06-03 |
| NCT06490237CHU de ReimsCoding of Speech Signals in the Human Auditory Nerve | 2027-06-07 |
| NCT06370351SensorionA Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 42 studies in Deafness with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study intends to assess safety, tolerability, and efficacy of SENS-601, injected with SPHYNX administration system, in children between 6 months and 6 years of age, with hearing loss related to pathogenic variation(s) of GJB2 gene.
160 studies on the registry are indexed under Deafness; 46 are open to participants now.
This study's planned enrollment of 18 is below the median of 43 across 106 interventional studies indexed under Deafness.
Browse Deafness studies →Sensorion is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Compared within Deafness, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hearing Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intracochlear administration of Dose level 1 of SENS-601 in one ear, with the SPHYNX injection system
Combination Product: SENS-601 administration
Intracochlear administration of Dose level 2 of SENS-601 in one ear, with the SPHYNX injection system
Combination Product: SENS-601 administration
Intracochlear administration of SENS-601 in both ears, with the SPHYNX injection system, at the dose recommended following the Dose escalation phase
Combination Product: SENS-601 administration
Administration of SENS-601 with the SPHYNX injection system
Safety and tolerability of SENS-601 and SPHYNX administration system
The incidence and severity of Treatment-Emergent Adverse Events (TEAEs). The incidence and severity of Adverse Device Events, Serious Adverse Device Effects, and Device Deficiencies
Time frame: 5 years
Efficacy of SENS-601 assessed by ABR
Change from baseline of hearing threshold measured by auditory brainstem response (ABR)
Time frame: 5 years
Efficacy of SENS-601 assessed by PTA
Change from baseline of hearing threshold measured by pure-tone audiometry (PTA)
Time frame: 5 years
SPHYNX Injection system performance
Incidence of successful administrations, based on user questionnaires
Time frame: Day 1
SPHYNX Injection System clinical benefit
Incidence of failed surgeries due to SPHYNX injection system, based on "SENS-601 injection form" user questionnaires
Time frame: Day 1
Usability of the administration system
Evaluation of the degree to which users were able to effectively, efficiently, and safely use the devices in their specific environments, based on "Usability assessment" user questionnaire
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2034, 95 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sensorion